<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720976</url>
  </required_header>
  <id_info>
    <org_study_id>JAB-3312-1003</org_study_id>
    <nct_id>NCT04720976</nct_id>
  </id_info>
  <brief_title>JAB-3312 Activity in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination With Pembrolizumab or Binimetinib in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobio Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jacobio Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens&#xD;
      in adult participants with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of&#xD;
      JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid&#xD;
      tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle. (Dose escalation phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR is defined as the proportion of participants with complete response or partial response (CR+PR). (Dose expansion phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first. (Dose expansion phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>DCR is defined as proportion of participants with complete response, partial response, stable disease(CR+PR+SD). (Dose expansion phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first. (Dose expansion phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the interval of time between the date of first treatment until death, loss to follow up or termination of the study by the sponsor. (Dose expansion phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR is defined as the proportion of participants with complete response or partial response (CR+PR). (Dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response ( DOR )</measure>
    <time_frame>24 months</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first. (Dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response ( DCR )</measure>
    <time_frame>24 months</time_frame>
    <description>DCR is defined as proportion of participants with complete response, partial response, stable disease(CR+PR+SD). (Dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first. (Dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the interval of time between the date of first treatment until death, loss to follow up or termination of the study by the sponsor(Dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Highest observed plasma concentration of JAB-3312(dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Time of highest observed plasma concentration of JAB-3312(dose escalation phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>24 months</time_frame>
    <description>Area under the plasma concentration time curve of JAB-3312(dose escalation phase)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>JAB-3312+Pembrolizumab dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JAB-3312+ Binimetinib dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation part2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JAB-3312+Pembrolizumab dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion part1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JAB-3312+Binimetinib dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion part2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-3312</intervention_name>
    <description>JAB-3312 will be administered orally, variable dose.</description>
    <arm_group_label>JAB-3312+ Binimetinib dose escalation</arm_group_label>
    <arm_group_label>JAB-3312+Binimetinib dose expansion</arm_group_label>
    <arm_group_label>JAB-3312+Pembrolizumab dose escalation</arm_group_label>
    <arm_group_label>JAB-3312+Pembrolizumab dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Binimetinib will be administered orally.</description>
    <arm_group_label>JAB-3312+ Binimetinib dose escalation</arm_group_label>
    <arm_group_label>JAB-3312+Binimetinib dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered as an intravenous infusion.</description>
    <arm_group_label>JAB-3312+Pembrolizumab dose escalation</arm_group_label>
    <arm_group_label>JAB-3312+Pembrolizumab dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent, according to local guidelines, signed and dated by the&#xD;
             participant prior to the performance of any study-specific procedures, sampling, or&#xD;
             analyses.&#xD;
&#xD;
          -  Participant must be ≥18 years of age at the time of signature of the informed consent&#xD;
             form (ICF).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.&#xD;
&#xD;
          -  Sufficient organ function&#xD;
&#xD;
          -  Participants with a life expectancy ≥3 months&#xD;
&#xD;
          -  Participants must have at least 1 measurable lesion as defined by Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancer that is histologically distinct from the cancers under study&#xD;
&#xD;
          -  Brain or spinal metastases&#xD;
&#xD;
          -  History of severe autoimmune disease or autoimmune disorder that requires chronic&#xD;
             systemic corticosteroid treatment.&#xD;
&#xD;
          -  Has active hepatitis B, or hepatitis C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacobio Pharmaceuticals</last_name>
    <phone>86 10 56315466</phone>
    <email>clinicaltrials@jacobiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

